Posted by Michael Wonder on 18 Feb 2023
Pfizer announces positive Talzenna and Xtandi combination data from Phase 3 TALAPRO-2 trial
16 February 2023 - Supplemental new drug application for Talzenna and Xtandi combination granted US FDA priority review.
The US FDA has granted priority review for Pfizer’s supplemental new drug application for Talzenna in combination with Xtandi for the treatment of men with metastatic castration-resistant prostate cancer.
